NEWS
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics (NASDAQ: ATHE) has reported positive interim data from its ATH434-202 Phase 2 clinical trial for multiple system atrophy (MSA). Key findings include:
▪️43% of participants showed improvement in daily living activities
29% had stable or improved neurological symptoms
29% had stable or improved neurological symptoms
▪️Objective biomarkers demonstrated improvement consistent with clinical findings
▪️ATH434 was well-tolerated with no safety signals detected
▪️The interim analysis included data from 7 participants treated for 6 months and neuroimaging data from 3 participants treated for 12 months.
▪️Clinical responders showed reduced iron accumulation in key brain areas and stable levels of NFL, a marker of axonal injury.
▪️These results suggest ATH434's potential to modify the course of MSA, particularly in less advanced cases.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2683Followers
108Following
29KVisitors
Follow